MedTrace Logo

Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma

NCT02205047 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2025-07-31

No results posted yet for this study

Summary

The purpose of this study is to find out whether either trastuzumab or the combination of trastuzumab and pertuzumab with standard chemotherapy shows more activity against gastro-oesophageal adenocarcinoma than standard chemotherapy given before and after surgery and it can be safely administered.

Conditions

  • Malignant Neoplasm of Stomach
  • Malignant Neoplasm of Cardio-esophageal Junction of Stomach
  • Epidermal Growth Factor Receptor (EGFR) Protein Overexpression

Interventions

DRUG

Cisplatin

DRUG

5-fluorouracil or Capecitabine

DRUG

Trastuzumab

DRUG

Pertuzumab

PROCEDURE

gastrectomy

D2 gastrectomy

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Anna Dorothea Wagner, MD · Centre hospitalier universitaire vaudois, Lausanne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-15
Primary Completion
2022-12-22
Completion
2024-12-31

Countries

  • Belgium
  • Estonia
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Portugal
  • Singapore
  • South Korea
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02205047 on ClinicalTrials.gov